Advertisement

Topics

Epygenix Therapeutics Receives US FDA Orphan Drug Designation for EPX-300 for the Treatment of ...

08:00 EDT 23 Aug 2017 | BioMedReports - Blog

PARAMUS, N.J., Aug. 23, 2017/PRNewswire/ -- Epygenix Therapeutics, Inc., a privately held biopharmaceutical company developing precision medicine for rare and catastrophic forms of genetic

Read more...

Original Article: Epygenix Therapeutics Receives US FDA Orphan Drug Designation for EPX-300 for the Treatment of ...

NEXT ARTICLE

More From BioPortfolio on "Epygenix Therapeutics Receives US FDA Orphan Drug Designation for EPX-300 for the Treatment of ..."

Advertisement
Quick Search
Advertisement
Advertisement